The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Open accessAbstract
Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly sought. Medical records of 100 patients with CML who were in MR 4.5 and discontinued their TKI outside clinical trials were reviewed. After a median follow-up of 30 months (range, 5–112 months) after discontinuation, 35% and 17% lost MR 4.5 and major molecular response (MMR), respectively. Only six patients lost MMR 12 months or more after discontinuation. Loss of MR 4.5 was observed in 29% and 7% of patients with sustained MR 4.5 duration of more than 2 and 6 years before discontinuation, respectively. By univariate analysis, there was a higher risk of loss of MR 4.5 for patients who were treated for less than 87 months, received second or subsequent line TKI, never received interferon, or those with sustained MR 4.5 for less than 6 years. By multivariate analysis, sustained MR 4.5 for 6 years or more was the only significant predictor for durable response. Overall, 30% of patients who discontinued while in MR 4.5 were retreated with 93% regaining MR 4.5 at a median of 5 months. These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting. MR 4.5 duration of 6 years or more before discontinuation is associated with very low risk of loss of MR 4.5 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5797 · Cited by 416
Research works printed but not linked: 31
- O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. · DOI · Paper page
- Kantarjian H, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–7. · DOI · Paper page
- Cortes JE, et al. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the BFORE trial. J Clin Oncol. 2017;35:7002. · doi:10.1200/jco.2017.35.15_suppl.7002
- Cortes JE, et al. Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–U54. · DOI · Paper page
- Hochhaus A, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30(1):57–64. · DOI
- Benjamini O, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014;55(12):2879–86. · DOI
- Falchi L, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88(12):1024–9. · DOI
- Doggrell SA, Christensen AM. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–70. Expert Opin Pharmacother. 2011;12(1):157–63. · DOI
- Baccarani M, et al. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94:S141–7. · DOI · Paper page
- Dusetzina SB, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. · DOI · Paper page
- Douxfils J, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival a systematic review and meta-analysis. Jama Oncology. 2016;2(5):625–32. · DOI · Paper page
- Ault P, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204–8. · DOI · Paper page
- Pye SM, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–8. · DOI · Paper page
- Cortes JE, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–5. · DOI
- Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. · DOI · Paper page
- Ross DM, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22. · DOI · Paper page
- Mahon FX, et al. Interim analysis of a Pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia : the EURO-SKI study. Blood. 2014;124(21):151. · DOI
- Rea D, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–54. · DOI · Paper page
- Hochhaus A, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–31. · DOI · Paper page
- Imagawa J, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–35. · DOI · Paper page
- Tanaka C, et al. GADD34 suppresses wound healing by upregulating expression of myosin IIA. Transgenic Res. 2010;19(4):637–45. · doi:10.1007/s11248-009-9347-z
- Isobe N, Hosoda K, Yoshimura Y. Immunolocalization of lingual antimicrobial peptide (LAP) in the bovine mammary gland. Anim Sci J. 2009;80(4):446–50. · doi:10.1111/j.1740-0929.2009.00652.x
- Goda A, et al. Heart failure with preserved versus reduced left ventricular systolic function: a prospective cohort of Shinken Database 2004-2005. J Cardiol. 2010;55(1):108–16. · doi:10.1016/j.jjcc.2009.10.009
- Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23. · DOI · Paper page
- Baccarani M, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51. · DOI · Paper page
- Hughes TP, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65. · DOI · Paper page
- Gunnarsson N, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169(5):683–8. · DOI
- Gugliotta G, et al. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica. 2017;102(9):1530–6. · doi:10.3324/haematol.2017.169532
- Verma D, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16):4353–8. · doi:10.1182/blood-2011-06-362889
- Goldman JM, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888–95. · DOI
- Etienne G, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298. · DOI · Paper page
Cited by
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25792 · Cited by 410
Self-citationMetal nanoparticles as a promising technology in targeted cancer treatment
Xu, J.-J., Zhang, W.-C., Guo, Y.-W., Chen, X.-Y., & Zhang, Y.-N. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2039804 · Cited by 276
Aissa, A. F., Islam, A. B. M. M. K., Ariss, M. M., Go, C. C., Rader, A. E., Conrardy, R. D., Gajda, A. M., Rubio-Perez, C., Valyi-Nagy, K., Pasquinelli, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21884-z · Cited by 273
Metadata
- Authors
- Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G. N., Issa, G. C., Rios, M. B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., Daver, N., Konopleva, M., DiNardo, C. D., Kadia, T., Pemmaraju, N., Jabbour, E., & Cortes, J.
- Venue
- Journal of Hematology & Oncology
- Published
- 2019-01-03
- Volume
- 12
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2913116303
- Cited by
- 174
- References
- 1
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. https://app.cochat.ai/papers/10.1186/s13045-018-0686-1
- The paper
- Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G. N., Issa, G. C., Rios, M. B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., Daver, N., Konopleva, M., DiNardo, C. D., Kadia, T., Pemmaraju, N., Jabbour, E., & Cortes, J. (2019). Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-018-0686-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.